Comparative Efficacy of Endoscopic Sleeve Gastroplasty (Esg) Versus Liraglutide in Weight Loss and Remission Of Obesity-Related Comorbidities: Twelve Months Follow-Up Results.

Nigro S, Vinciguerra F, Guccione F, Alibrandi A, Filannino R, Navarra G

Obesity surgery8 Aug 2025

PMID40779281DOI10.1007/s11695-025-08155-2PepBankPUB-40779281

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with class I or II obesity, liraglutide produced lower percentage excess weight loss than endoscopic sleeve gastroplasty at 3 months (P=0.001).
In plain wordsIn people with obesity, liraglutide led to less excess weight loss than endoscopic sleeve gastroplasty at 3 months.
Peptide
Liraglutide
Outcome
Decreasepercentage excess weight loss at 3 months
Study
n = 43
Comparator
endoscopic sleeve gastroplasty
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
P-value
0.001
reported early weight-loss contrasts
Source sentences
Summary
After 3 and 6 months, %EWL and %TWL were greater in the ESG group (P = 0.001).
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective, randomized controlled, monocentric study was performed.
Summary · context
A total of 43 patients with class I and II obesity were included in the study.
Summary · context
Twenty-three patients underwent ESG, and 20 patients were treated with Liraglutide.
Summary · context
All participants received standardized follow-up protocols with assessments by both surgeon and nutritionist in the bariatric ambulatory setting.
Report a problemFND-4077928101
02HumanRandomized controlled trialEfficacy outcome
In patients with class I or II obesity, liraglutide produced lower percentage total weight loss than endoscopic sleeve gastroplasty at 3 months (P=0.001).
In plain wordsIn people with obesity, liraglutide led to less total weight loss than endoscopic sleeve gastroplasty at 3 months.
Peptide
Liraglutide
Outcome
Decreasepercentage total weight loss at 3 months
Study
n = 43
Comparator
endoscopic sleeve gastroplasty
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
P-value
0.001
reported early weight-loss contrasts
Source sentences
Summary
After 3 and 6 months, %EWL and %TWL were greater in the ESG group (P = 0.001).
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective, randomized controlled, monocentric study was performed.
Summary · context
A total of 43 patients with class I and II obesity were included in the study.
Summary · context
Twenty-three patients underwent ESG, and 20 patients were treated with Liraglutide.
Summary · context
All participants received standardized follow-up protocols with assessments by both surgeon and nutritionist in the bariatric ambulatory setting.
Report a problemFND-4077928102
03HumanRandomized controlled trialEfficacy outcome
In patients with class I or II obesity, liraglutide produced lower percentage excess weight loss than endoscopic sleeve gastroplasty at 6 months (P=0.001).
In plain wordsIn people with obesity, liraglutide led to less excess weight loss than endoscopic sleeve gastroplasty at 6 months.
Peptide
Liraglutide
Outcome
Decreasepercentage excess weight loss at 6 months
Study
n = 43
Comparator
endoscopic sleeve gastroplasty
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
P-value
0.001
reported early weight-loss contrasts
Source sentences
Summary
After 3 and 6 months, %EWL and %TWL were greater in the ESG group (P = 0.001).
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective, randomized controlled, monocentric study was performed.
Summary · context
A total of 43 patients with class I and II obesity were included in the study.
Summary · context
Twenty-three patients underwent ESG, and 20 patients were treated with Liraglutide.
Summary · context
All participants received standardized follow-up protocols with assessments by both surgeon and nutritionist in the bariatric ambulatory setting.
Report a problemFND-4077928103
04HumanRandomized controlled trialEfficacy outcome
In patients with class I or II obesity, liraglutide produced lower percentage total weight loss than endoscopic sleeve gastroplasty at 6 months (P=0.001).
In plain wordsIn people with obesity, liraglutide led to less total weight loss than endoscopic sleeve gastroplasty at 6 months.
Peptide
Liraglutide
Outcome
Decreasepercentage total weight loss at 6 months
Study
n = 43
Comparator
endoscopic sleeve gastroplasty
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
P-value
0.001
reported early weight-loss contrasts
Source sentences
Summary
After 3 and 6 months, %EWL and %TWL were greater in the ESG group (P = 0.001).
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective, randomized controlled, monocentric study was performed.
Summary · context
A total of 43 patients with class I and II obesity were included in the study.
Summary · context
Twenty-three patients underwent ESG, and 20 patients were treated with Liraglutide.
Summary · context
All participants received standardized follow-up protocols with assessments by both surgeon and nutritionist in the bariatric ambulatory setting.
Report a problemFND-4077928104
05HumanRandomized controlled trialEfficacy outcome
In patients with class I or II obesity, liraglutide and endoscopic sleeve gastroplasty did not differ significantly in percentage excess weight loss at 12 months.
In plain wordsIn people with obesity, liraglutide and endoscopic sleeve gastroplasty showed no significant excess weight loss difference at 12 months.
Peptide
Liraglutide
Outcome
No significant changepercentage excess weight loss at 12 months
Study
n = 43
Comparator
endoscopic sleeve gastroplasty
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
However, at 12 months, these differences were no longer statistically significant, suggesting that the ESG group was experiencing some weight regain, while the Liraglutide group had a slower but more consistent weight loss.
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective, randomized controlled, monocentric study was performed.
Summary · context
A total of 43 patients with class I and II obesity were included in the study.
Summary · context
Twenty-three patients underwent ESG, and 20 patients were treated with Liraglutide.
Summary · context
All participants received standardized follow-up protocols with assessments by both surgeon and nutritionist in the bariatric ambulatory setting.
Report a problemFND-4077928105
06HumanRandomized controlled trialEfficacy outcome
In patients with class I or II obesity, liraglutide and endoscopic sleeve gastroplasty did not differ significantly in percentage total weight loss at 12 months.
In plain wordsIn people with obesity, liraglutide and endoscopic sleeve gastroplasty showed no significant total weight loss difference at 12 months.
Peptide
Liraglutide
Outcome
No significant changepercentage total weight loss at 12 months
Study
n = 43
Comparator
endoscopic sleeve gastroplasty
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
However, at 12 months, these differences were no longer statistically significant, suggesting that the ESG group was experiencing some weight regain, while the Liraglutide group had a slower but more consistent weight loss.
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective, randomized controlled, monocentric study was performed.
Summary · context
A total of 43 patients with class I and II obesity were included in the study.
Summary · context
Twenty-three patients underwent ESG, and 20 patients were treated with Liraglutide.
Summary · context
All participants received standardized follow-up protocols with assessments by both surgeon and nutritionist in the bariatric ambulatory setting.
Report a problemFND-4077928106
07HumanRandomized controlled trialEfficacy outcome
In patients with class I or II obesity, liraglutide and endoscopic sleeve gastroplasty did not differ significantly in resolution of obesity-related comorbidities at 3 months.
In plain wordsIn people with obesity, liraglutide and endoscopic sleeve gastroplasty showed no significant comorbidity resolution difference at 3 months.
Peptide
Liraglutide
Outcome
No significant changeresolution of obesity-related comorbidities at 3 months
Study
n = 43
Comparator
endoscopic sleeve gastroplasty
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Regarding the resolution of comorbidities, there were no statistically significant differences at 3, 6 and 12 months between the two groups.
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective, randomized controlled, monocentric study was performed.
Summary · context
A total of 43 patients with class I and II obesity were included in the study.
Summary · context
Twenty-three patients underwent ESG, and 20 patients were treated with Liraglutide.
Summary · context
All participants received standardized follow-up protocols with assessments by both surgeon and nutritionist in the bariatric ambulatory setting.
Report a problemFND-4077928107
08HumanRandomized controlled trialEfficacy outcome
In patients with class I or II obesity, liraglutide and endoscopic sleeve gastroplasty did not differ significantly in resolution of obesity-related comorbidities at 6 months.
In plain wordsIn people with obesity, liraglutide and endoscopic sleeve gastroplasty showed no significant comorbidity resolution difference at 6 months.
Peptide
Liraglutide
Outcome
No significant changeresolution of obesity-related comorbidities at 6 months
Study
n = 43
Comparator
endoscopic sleeve gastroplasty
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Regarding the resolution of comorbidities, there were no statistically significant differences at 3, 6 and 12 months between the two groups.
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective, randomized controlled, monocentric study was performed.
Summary · context
A total of 43 patients with class I and II obesity were included in the study.
Summary · context
Twenty-three patients underwent ESG, and 20 patients were treated with Liraglutide.
Summary · context
All participants received standardized follow-up protocols with assessments by both surgeon and nutritionist in the bariatric ambulatory setting.
Report a problemFND-4077928108
09HumanRandomized controlled trialEfficacy outcome
In patients with class I or II obesity, liraglutide and endoscopic sleeve gastroplasty did not differ significantly in resolution of obesity-related comorbidities at 12 months.
In plain wordsIn people with obesity, liraglutide and endoscopic sleeve gastroplasty showed no significant comorbidity resolution difference at 12 months.
Peptide
Liraglutide
Outcome
No significant changeresolution of obesity-related comorbidities at 12 months
Study
n = 43
Comparator
endoscopic sleeve gastroplasty
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Regarding the resolution of comorbidities, there were no statistically significant differences at 3, 6 and 12 months between the two groups.
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective, randomized controlled, monocentric study was performed.
Summary · context
A total of 43 patients with class I and II obesity were included in the study.
Summary · context
Twenty-three patients underwent ESG, and 20 patients were treated with Liraglutide.
Summary · context
All participants received standardized follow-up protocols with assessments by both surgeon and nutritionist in the bariatric ambulatory setting.
Report a problemFND-4077928109
10HumanRandomized controlled trialEfficacy outcome
In class I/II obesity trial participants, the liraglutide group had slower but more consistent weight loss than the ESG group at the 12-month comparison; no trajectory-specific coefficient was stated.
In plain wordsIn people with obesity, liraglutide had slower but more consistent weight loss than endoscopic sleeve gastroplasty; the trajectory estimate was unspecified.
Peptide
Liraglutide
Outcome
Direction not reportedQualitative weight-loss trajectory at 12-month comparison
Study
n = 43
Comparator
endoscopic sleeve gastroplasty
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
However, at 12 months, these differences were no longer statistically significant, suggesting that the ESG group was experiencing some weight regain, while the Liraglutide group had a slower but more consistent weight loss.
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective, randomized controlled, monocentric study was performed.
Summary · context
A total of 43 patients with class I and II obesity were included in the study.
Summary · context
Twenty-three patients underwent ESG, and 20 patients were treated with Liraglutide.
Summary · context
All participants received standardized follow-up protocols with assessments by both surgeon and nutritionist in the bariatric ambulatory setting.
Report a problemFND-4077928112

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

11HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In patients with class I or II obesity, no patients had major complications during liraglutide or endoscopic sleeve gastroplasty treatment.
In plain wordsIn patients with obesity, no major complications were reported with liraglutide or endoscopic sleeve gastroplasty.
Peptide
Liraglutide
Outcome
Not applicablemajor complications
Study
n = 43
Outcome group
Adverse events · Whole body
Source sentences
Summary
None of the patients had major complications or significant side effects.
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective, randomized controlled, monocentric study was performed.
Summary · context
A total of 43 patients with class I and II obesity were included in the study.
Summary · context
Twenty-three patients underwent ESG, and 20 patients were treated with Liraglutide.
Summary · context
All participants received standardized follow-up protocols with assessments by both surgeon and nutritionist in the bariatric ambulatory setting.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4077928110
12HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In patients with class I or II obesity, no patients had significant side effects during liraglutide or endoscopic sleeve gastroplasty treatment.
In plain wordsIn patients with obesity, no significant side effects were reported with liraglutide or endoscopic sleeve gastroplasty.
Peptide
Liraglutide
Outcome
Not applicablesignificant side effects
Study
n = 43
Outcome group
Adverse events · Whole body
Source sentences
Summary
None of the patients had major complications or significant side effects.
4 context sentences(design, population, supporting numbers)
Summary · context
A prospective, randomized controlled, monocentric study was performed.
Summary · context
A total of 43 patients with class I and II obesity were included in the study.
Summary · context
Twenty-three patients underwent ESG, and 20 patients were treated with Liraglutide.
Summary · context
All participants received standardized follow-up protocols with assessments by both surgeon and nutritionist in the bariatric ambulatory setting.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4077928111

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.